Report cover image

Asia Pacific Apheresis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Publisher Mordor Intelligence Inc
Published Aug 14, 2025
Length 110 Pages
SKU # MOI20478287

Description

Asia Pacific Apheresis Market Analysis

The Asia Pacific Apheresis Market size is estimated at USD 0.82 billion in 2025, and is expected to reach USD 1.35 billion by 2030, at a CAGR of 10.57% during the forecast period (2025-2030).

Rapid adoption of automated blood-component technologies, expanding CAR-T cell therapy logistics, and public investment under national healthcare agendas such as “Healthy China 2030” collectively amplify procedure volumes across the region. Hospitals and blood centers are modernizing collection rooms with next-generation systems that shorten processing times, while research institutes channel grant funding toward cell-therapy-oriented leukapheresis platforms. Meanwhile, strategic localization by multinationals reduces import lead times and aligns with government procurement mandates, deepening supplier loyalty. Market risks persist around reimbursement gaps, consumable-approval inconsistencies, and shortages of certified operators, yet rising demand for precision therapies continues to outweigh these constraints, sustaining a robust long-term growth outlook for the Asia Pacific apheresis market.

Asia Pacific Apheresis Market Trends and Insights

Growth of National Blood Component Initiatives

Government-backed blood-safety programs are reshaping procedure volumes as China upgrades more than 450 blood centers under its “Healthy China 2030” roadmap. Capital expenditure aims squarely at automated component separation, illustrated by Terumo’s USD 15 million facility in Hangzhou that manufactures Trima Accel kits locally, lowering unit cost and reducing customs delays. Indonesia’s first plasma-fractionation plant targeting 600,000 liters by 2026 underscores a region-wide shift toward self-sufficiency. Standardized procurement frameworks emerging from these programs favor systems with closed-loop traceability and virus-inactivation modules, reinforcing purchasing preferences for premium platforms and propelling the Asia Pacific apheresis market.

Public Investment in Thrombocytopenia Treatment

Japan, Australia, and South Korea are front-loading budgets to secure platelet supply as aging demographics and oncology caseloads intensify. The Japanese Red Cross “Nara Regimen” expands certified operator pools through university-linked training that enhances competence on automated plateletpheresis devices. Evidence from Sanquin’s deployment of Reveos shows platelet units produced per donor rising from four to five, yielding a 20% cost saving per unit. These economics encourage ministries of health to underwrite disposable budgets, accelerating uptake in the Asia Pacific apheresis market.

Limited Reimbursement Frameworks Across Most APAC Nations

Fee schedules in emerging markets seldom cover disposables fully, leaving providers to absorb 20–40% of procedure cost for therapeutic apheresis. South Korea’s overhaul of generic-drug pricing illustrates policymaker focus on budget ceilings rather than procedure expansion. India’s Rare Diseases Policy highlights fiscal constraints, allocating only USD 3.6 million annually for a population of 1.4 billion. Consequently, cash-pay models dominate, curtailing patient access and capping near-term growth for the Asia Pacific apheresis market.

Other drivers and restraints analyzed in the detailed report include:

  1. Accelerated Adoption of Advanced Plasmapheresis Technologies
  2. Integration of Apheresis in CAR-T Therapy Logistics
  3. Shortage of Specialized Apheresis Personnel

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Recurring demand for tubing sets, separation kits, and filters kept disposables at 62.33% of Asia Pacific apheresis market share in 2024. Steady procedure growth, stringent sterility rules, and single-use mandates ensure predictable volume gains. Bundled-pricing contracts negotiated by national blood services enhance vendor lock-in, stabilizing margins. Meanwhile, the devices segment, supported by a 14.08% CAGR, benefits from replacement cycles for legacy centrifuges reaching end-of-life and from automation upgrades that cut operator intervention by up to 65%. Fresenius Kabi’s Adaptive Nomogram software, cleared by the FDA, exemplifies how analytics overlays deliver incremental performance, persuading budget-constrained hospitals to refresh fleets.

Hospitals increasingly demand integrated platforms whereby proprietary disposables synchronize with device firmware, anchoring long-run consumable revenue for suppliers. Terumo’s Reveos platform reduces manual steps from 26 to 9, improving throughput and releasing staff for value-added clinical tasks. Competitive intensity revolves around field-service coverage and software interoperability, elevating the Asia Pacific apheresis market size tied to premium devices that interlock data with electronic medical records.

Plasmapheresis accounted for 42.87% of total procedure revenue in 2024 as plasma-derived immunoglobulin demand rises among aging populations. National plasma-fractionation targets push hospitals to increase donor recruitment, sustaining steady kit consumption. Leukapheresis, forecast to grow at 12.87% CAGR, capitalizes on hematology and CAR-T pipelines that require high-purity mononuclear cell collections. Clinical trials in China showed optimized centrifugation protocols lowering leukocytosis within two hours while preserving viability, supporting broader therapy adoption.

Plateletpheresis remains indispensable for oncology support, yet volume growth stabilizes as process efficiencies emerge. Erythrocytapheresis gains niche traction in sickle-cell programs, notably in India’s tribal regions where prevalence exceeds 1.8%. Emerging modalities such as photopheresis and lipid-apheresis attract specialist centers, offering upside to the Asia Pacific apheresis industry as regulatory approvals widen.

The Asia Pacific Apheresis Market Report is Segmented by Product (Devices, Disposables), Procedure (Plasmapheresis, and More), Indication (Renal Disorders, and More), Technology (Centrifugal Separation, Membrane Separation), End User (Hospitals & Transfusion Centers, and More), and Country (China, Japan, India, South Korea, Australia & New Zealand, Rest of Asia Pacific). The Market Forecasts are Provided in Terms of Value (USD).

List of Companies Covered in this Report:

  1. Terumo
  2. Asahi Kasei (Medical)
  3. Fresenius
  4. Haemonetics
  5. Kaneka
  6. B. Braun
  7. Cerus
  8. Grifols
  9. MacoPharma
  10. Kawasumi Laboratories
  11. Nikkiso Co., Ltd.
  12. JMS Co., Ltd.
  13. GVS S.p.A.
  14. Miltenyi Biotec
  15. Stem Cell Technologies
  16. HemaCare (Charles River)
  17. Medica S.p.A.
  18. Biosafe SA (GE-Cytiva)
  19. Nigale Biotech
  20. Immucor
  21. Terumo Blood and Cell Technologies

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

110 Pages
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growth of National Blood Component Initiatives
4.2.2 Public Investment in Thrombocytopenia Treatment
4.2.3 Accelerated Adoption of Advanced Plasmapheresis Technologies
4.2.4 Integration of Apheresis in CAR-T Therapy Logistics
4.2.5 Public–Private Partnerships Enhancing Equipment Access
4.2.6 Rising Demand for Personalized and Precision Therapies
4.3 Market Restraints
4.3.1 Limited Reimbursement Frameworks Across Most APAC Nations
4.3.2 Shortage of Specialized Apheresis Personnel
4.3.3 Restrictions on Single-Use Plastic Imports
4.3.4 Inconsistent Regulatory Approvals for Consumables
4.4 Regulatory Landscape
4.5 Technological Outlook
4.6 Porter’s Five Forces Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitutes
4.6.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value in USD)
5.1 By Product
5.1.1 Devices
5.1.2 Disposables
5.2 By Procedure
5.2.1 Plasmapheresis
5.2.2 Plateletpheresis
5.2.3 Erythrocytapheresis
5.2.4 Leukapheresis
5.2.5 Other Procedures
5.3 By Indication
5.3.1 Renal Disorders
5.3.2 Hematological Disorders
5.3.3 Neurological Disorders
5.3.4 Autoimmune Disorders
5.3.5 Other Indications
5.4 By Technology
5.4.1 Centrifugal Separation
5.4.2 Membrane Separation
5.5 By End User
5.5.1 Hospitals & Transfusion Centers
5.5.2 Blood Banks
5.5.3 Research & Academic Institutes
5.6 By Country
5.6.1 China
5.6.2 Japan
5.6.3 India
5.6.4 South Korea
5.6.5 Australia & New Zealand
5.6.6 Rest of Asia Pacific
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products & Services, and Recent Developments)
6.3.1 Terumo Corporation
6.3.2 Asahi Kasei (Medical)
6.3.3 Fresenius SE & Co. KGaA
6.3.4 Haemonetics Corporation
6.3.5 Kaneka Corporation
6.3.6 B. Braun Melsungen AG
6.3.7 Cerus Corporation
6.3.8 Grifols S.A.
6.3.9 Macopharma
6.3.10 Kawasumi Laboratories
6.3.11 Nikkiso Co., Ltd.
6.3.12 JMS Co., Ltd.
6.3.13 GVS S.p.A.
6.3.14 Miltenyi Biotec
6.3.15 STEMCELL Technologies
6.3.16 HemaCare (Charles River)
6.3.17 Medica S.p.A.
6.3.18 Biosafe SA (GE-Cytiva)
6.3.19 Nigale Biotech
6.3.20 Immucor Inc.
6.3.21 Terumo Blood and Cell Technologies
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us